RxDoctor Payments Data

Natthavat Tanphaichitr, MD

Nephrology · Akron, OHNPI 1669587523

Payments from drug & device makers

$1,466in general payments, 2019–2025

Across 48 payments — averaging $30.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$271
  • Fresenius USA Marketing, Inc.$227
  • Otsuka America Pharmaceutical, Inc.$209
  • Mallinckrodt Hospital Products Inc.$160
  • AstraZeneca$153
  • Novartis$140
  • plus $306 from 6 others

What the payments were for

  • Food & beverage$1,30289%
  • Education$16411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,466 in reported general payments places this provider in the 55th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$206,088
Medicare patients
492
Services billed
1,890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide62$143,561
XphozahTenapanor Hcl36$104,471
FarxigaDapagliflozin Propanediol92$79,069
LokelmaSodium Zirconium Cyclosilicate23$23,786
VeltassaPatiromer Calcium Sorbitex13$16,071
Sevelamer Carbonate83$11,604
Cinacalcet Hcl18$6,169
Febuxostat21$2,055
Potassium Chloride22$1,114
Torsemide38$1,016
Calcitriol72$1,011
Olmesartan Medoxomil76$915
Calcium Acetate14$824
Furosemide81$745
Chlorthalidone45$721

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$227$143,56162 claims
AstraZenecaFarxiga, Lokelma$153$102,856115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 450 nephrology providers in Ohio.

Other nephrology in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →